Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Author:

Mayor Neema P.12ORCID,Wang Tao34,Lee Stephanie J.56ORCID,Kuxhausen Michelle5,Vierra-Green Cynthia5,Barker Dominic J.1,Auletta Jeffrey7,Bhatt Vijaya R.8ORCID,Gadalla Shahinaz M.9ORCID,Gragert Loren10ORCID,Inamoto Yoshihiro11ORCID,Morris Gerald P.12ORCID,Paczesny Sophie13ORCID,Reshef Ran14ORCID,Ringdén Olle15ORCID,Shaw Bronwen E.4ORCID,Shaw Peter16ORCID,Spellman Stephen R.5ORCID,Marsh Steven G. E.12ORCID

Affiliation:

1. Anthony Nolan Research Institute, Royal Free Hospital, London, UK

2. UCL Cancer Institute, University College London, London, UK

3. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI

4. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

5. Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN

6. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

7. Blood and Marrow Transplant Program and Host Defense Program, Nationwide Children's Hospital, Columbus, OH

8. Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE

9. Division of Cancer Epidemiology and Genetics, NIH-NCI Clinical Genetics Branch, Rockville, MD

10. Tulane Cancer Center, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA

11. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

12. Department of Pathology, University of California San Diego, San Diego, CA

13. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC

14. Division of Hematology/Oncology and Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY

15. Department of Clinical Sciences, Intervention and Technology, Translational Cell Therapy Research Group, Karolinska Institute, Stockholm, Sweden

16. Department of Child and Adolescent Health, Cancer Centre for Children, The Children's Hospital at Westmead, Westmead, New South Wales, Australia

Abstract

PURPOSE Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hematopoietic cell transplantation, improving survival and reducing post-transplant complications. However, most studies included relatively small numbers of patients. Here we report the findings from a large, multicenter validation study. METHODS UHR HLA typing was available on 5,140 conventionally 10 out of 10 HLA-matched patients with malignant disease transplanted between 2008 and 2017. RESULTS After UHR HLA typing, 82% of pairs remained 10 out of 10 UHR-matched; 12.3% of patients were 12 out of 12 UHR HLA-matched. Compared with 12 out of 12 UHR-matched patients, probabilities of grade 2-4 acute graft-versus-host disease (aGVHD) were significantly increased with UHR mismatches (overall P = .0019) and in those patients who were HLA-DPB1 T-cell epitope permissively mismatched or nonpermissively mismatched (overall P = .0011). In the T-cell–depleted subset, the degree of UHR HLA mismatch was only associated with increased transplant-related mortality (TRM) (overall P = .0068). In the T-cell–replete subset, UHR HLA matching was associated with a lower probability of aGVHD (overall P = .0020); 12 out of 12 UHR matching was associated with reduced TRM risk when compared with HLA-DPB1 T-cell epitope permissively mismatched patients, whereas nonpermissive mismatching resulted in a greater risk (overall P = .0003). CONCLUSION This study did not confirm that UHR 12 out of 12 HLA matching increases the probability of overall survival but does demonstrate that aGVHD risk, and in certain settings TRM, is lowest in UHR HLA-matched pairs and thus warrants consideration when multiple 10 out of 10 HLA-matched donors of equivalent age are available.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3